Drug Trial Radar · NCT05550337
Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris
Last checked: Nov 19, 2026Latest source record: Sep 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
807
Actual
Start
Sep 19, 2022
Primary completion
May 9, 2023
Study completion May 9, 2023
Sponsor
- Lead sponsor
- Teva Pharmaceuticals USATeva (TEVA)
- Sponsor type
- Industry
- Collaborators
- Teva Pharmaceuticals, Inc.
- First posted
- Sep 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To compare the safety and efficacy of the test (Trifarotene 0.005% cream), placebo (vehicle cream) and reference AKLIEF® (Trifarotene 0.005% cream) treatments to demonstrate clinical equivalence in subjects with acne vulgaris.
Conditions
- Acne Vulgaris
Interventions
Trifarotene 0.005 % Topical CreamDrug
Cream
AKLIEF®Drug
Cream
PlaceboDrug
Cream
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Change in Inflammatory Lesion CountsTime frame: Baseline and 12 Weeks
- Primary Change in Non-Inflammatory Lesion CountTime frame: Baseline and 12 Weeks
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Site 10011
West Covina, California
Site 10001
Brandon, Florida
Site 10003
Fort Lauderdale, Florida
Site 10004
Miami, Florida
Site 10005
Miramar, Florida
Site 10002
Tampa, Florida
Site 10012
Baton Rouge, Louisiana
Site 10013
Baton Rouge, Louisiana
Site 10011
New Orleans, Louisiana
Site 10008
Las Cruces, New Mexico
Site 10010
Saint Clair, Pennsylvania
Site 10009
Dallas, Texas
Site 10006
El Paso, Texas
Site 10007
El Paso, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.